Associate Professor, Hematology and Medical Oncology, Emory University School of Medicine
Hematology
Dr. Leonard T. Heffner, MD
|
|
Give Review
Leonard T. Heffner works in the field of Hematology. He graduated from Baylor College of Medicine. He received awards:"Top MD". Leonard Heffner is a published doctor and has 28 publications published. The lastest was: 'A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgki...' Leonard T. Heffner accepts Medicare payments and is listed with Medicare.gov.
Publications
- A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgki...
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor Acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
- Predictors of survival outcomes in phase 1 relapsed or refractory multiple Myeloma patients.
- Predicting early blast transformation in chronic-phase chronic myeloid Leukemia: Is immunophenotyping the missing link?
- Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed Systemic AL amyloidosis.
- Consolidation and maintenance therapy with lenalidomide, bortezomib, dexamethasone (RVD) in high-risk Myeloma patients.
- Epsilon aminocaproic acid prevents bleeding in severely Thrombocytopenic patients with hematological malignancies.
- Treatment of adults with Acute lymphoblastic leukemia: Do the specifics of the regimen matter?: Results from a prospective randomized trial.
- High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
- Early clearance of peripheral blood blasts predicts response to induction chemotherapy in Acute myeloid leukemia.
- A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lym...
- Managing Chronic Myeloid Leukemia: A Coordinated Team Care Perspective.
- Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgk...
- High-dose cytarabine induction is well tolerated and active in patients with de novo Acute myeloid leukemia older than 60 years.
- Prognostic significance of leukopenia at the time of diagnosis in Acute myeloid leukemia.
- A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple Myeloma: a dose- and schedule-finding study.
- Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory Acute lymphoblastic leukemia.
- Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor Cell transplantation for multiple myeloma.
- Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial.
- Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed Systemic AL amyloidosis: results of a phase 1/2 study.
- A new formulation of vincristine for Acute lymphoblastic leukemia.
- Single-agent bortezomib in previously untreated multiple Myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neu...
- Breakthroughs in the management of multiple Myeloma.
- Peripheral blood monitoring of chronic myeloid Leukemia during treatment with imatinib, second-line agents, and beyond.
- Deep venous thromboses in patients with hematological malignancies after peripherally inserted Central venous catheters.
- Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple Myeloma.
- Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple Myeloma: a retrospective study.
Schools
Bowman Gray School Of Medicine
Baylor College Of Med
Emory University Hospital
Grady Mem Hospital
Jackson Mem HospJackson Health
Vet Affairs Med Center
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Burkitt's Lymphoma
- View All
Doctors Specialties
- Hematology
Accepted Insurances
Awards
- Top MD
Education
-
Jackson Memorial Hospital - Jackson Health System -
Baylor College of Medicine -
Emory University -
Wake Forest School of Medicine
Hospital
-
Emory University Hospital -
Emory University Hospital Midtown -
Grady Memorial Hospital
Drug Facts
| NPI NUMBER | 1780791533 | |
| NPPES Provider LastName | HEFFNER | |
| NPPES Provider FirstName | LEONARD | |
| NPPES Provider ZIPCode | 303221013 | |
| NPPES Provider State | GA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 1243.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 102.0 | |
| Percent Opioid Claims | 8.21 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1780791533 |
| Last Name Of The Provider | HEFFNER |
| First Name Of The Provider | LEONARD |
| View All |
Similar Doctors
|
|
Dr. Ha N. Tran, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Morgan L. McLemore, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ethan W. Tolbert, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kenneth A. Clark, MD |
|
|
Dr. Richard S. Leff, MD |
|
Dr. Douglas C. Collins, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Deepti A. Singh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Melvin R. Moore, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leon Bernal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rajasree P. Chowdry, MD |
|
|
Dr. Michael A. Briones, DO |
|
|
Dr. Shuang Y. Zhang, MD |